Pfizer Inc.

Pfizer Inc.

PFENYSEHealthcare
$29.58
up +0.14 (+0.48%)

1-Year Price

+8.71% past year
Pfizer Inc. (PFE) 1-year price chart: up 8.71% from $27.21 on Oct 2025 to $29.58 on Oct 2026. Closing range $23.67 to $29.58.

EquityGlimpse Score

Overall
5.8/10
Wide Moat

Strong, durable competitive advantages versus peers.

Growth
3

Valuation, profitability, financial health, dividend and sentiment scores for Pfizer Inc. (PFE) are available to EquityGlimpse members.

Market Cap
168.6B
P/E Ratio
18.31
EPS
$1.37
52W High
$29.88
52W Low
$23.62
Volume
28.59M
Beta
0.28
Dividend Yield
6.91%
Fair value estimate: sign up to see
Is PFE over- or undervalued? Run DCF and multiples models on EquityGlimpse.
See fair value

Key Financial Metrics

Price to Sales
2.26
Price to Book
1.64
EV/EBITDA
12.38
Free CF per Share
$1.60
Op. CF per Share
$2.06
Debt to Equity
0.78
Gross Margin
70.33%
Net Margin
12.42%

About Pfizer Inc.

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

CEO
Albert Bourla
Industry
Drug Manufacturers - General
Employees
75,000
IPO Date
1972-06-01
Country
US
Website
Unlock Full Analysis

Get the complete picture on Pfizer Inc.

Sign up for EquityGlimpse to access deep fundamental data, AI reports, valuation models, and real-time tracking for PFE and 8,500+ other stocks.

30 Years of Financials
Income statements, balance sheets, and cash flows with 70+ interactive charts
AI-Powered Analysis
Generate professional research reports with 15+ AI models
DCF Valuation
Run discounted cash flow models with customizable assumptions
Portfolio Tracking
Track real-time P&L, sector allocation, and dividend projections
Earnings Intelligence
Surprise tracking, revision momentum, and whisper estimates
Insider & Congress Trades
Monitor what insiders and Congress members are buying and selling

Starting at $8.25/month. 7-day free trial. Cancel anytime.